News and Announcements
Proteomics Commences Therapeutic Drug Discovery Program
- Published March 23, 2016 1:52PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
23rd Marc h 2016, ASX Announcement
Highlights:
- PILL to utilise its proprietary disruptive technology platform to assess potential new painkilling and antibiotic drug compounds.
- Therapeutic Drug Discovery is one of PILL’s core business areas and is a major growth market – peptide therapeutics market estimated value is $17b.
- Program is low cost and has potential deliver major end returns.
- PILL’s drug discovery process delivers a significant reduction in discovery timeline and a substantial cost advantage relative to traditional drug delivery
Life science company Proteomics International Laboratories Ltd (ASX: PIQ) (the Company, PILL) is pleased to announce that it has commenced a Therapeutic Drug Discovery program utilising its proprietary proteomics-based technology platform.
The Company is specifically targeting the discovery of new analgesic (painkilling) and antibiotics compounds and will test 50 – 100 venoms in the program. The program is low cost to PILL, with no additional costs incurred apart from sourcing the venom samples, and has the potential deliver highly significant end returns.
To view the full article please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
